RPTs offer a precision approach to patient treatment, delivering radioisotopes to tumors intravenously. By binding to tumor cells, RPTs bring radiation directly to cancer cells where they can induce cancer cell death and spare healthy cells.

Current RPT treatment options for gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have shown significant clinical benefit, however, while most patients experience disease control in clinical treatment with currently available options, patients will invariably progress. Most continue to live for at least two years without any approved treatments. There is an area of high unmet need for patient treatment options.

Alpha emitters are the next generation of therapeutic radionuclides and could be the preferred radionuclide over beta emitters for the treatment of solid tumors due to favorable chemistry and decay properties. Alpha radiation causes direct, irreparable double-stranded DNA breaks more frequently than beta radiation due to its higher linear energy transfer, while sparing surrounding healthy tissue due to its shorter path length.

Our lead programs leverage Actinium-225 (Ac225), a preferred alpha emitter. Ac225 may enhance RPT results, enabling efficacy in tumors with lower target expression and overcoming resistance to beta radiation, creating potentially better outcomes for patients.